CON
Concentra Group Holdings Parent, Inc.
CON's fundamentals are strong, but it looks expensive: trading at 25x earnings, above its usual 18x. Analysts expect strong earnings growth.
CON Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Under pressure |
CON's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
CON PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $26.73 | -38% |
| Fair | 18x | $30.20 | -30% |
| Expensive | 22x | $37.55 | -13% |
| Forward | 23x | $42.99 | — |
| Current | 25x | $42.99 | — |
Historical ranges are pointers, not guarantees.
CON's PE is in its expensive range at 25x. If earnings grow as analysts expect, today's price would be 23x next year's earnings.
CON Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CON, with profitability improving.
CON Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.87 | +11% |
| Q3 2026 | $1.69 | +40% |
| Q2 2026 | $1.55 | +29% |
| Q1 2026 | $1.39 | +3% |
| Q4 2025 | $1.30 | -9.7% |
| Q3 2025 | $1.21 | +13% |
| Q2 2025 | $1.20 | +7.1% |
| Q1 2025 | $1.35 | +30% |
| Q4 2024 | $1.44 | +41% |
CON earned $1.69 per share over the past year, up 40% from the year before.
CON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $622.1M | +8.6% |
| Q2 2026 | $606M | +10% |
| Q1 2026 | $569.6M | +14% |
| Q4 2025 | $539.1M | +16% |
| Q3 2025 | $572.8M | +17% |
| Q2 2025 | $550.8M | +15% |
| Q1 2025 | $500.8M | +7.1% |
| Q4 2024 | $465M | +5.5% |
CON's revenue has grown year over year every quarter since early 2024: $622M last quarter, up 8.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +2 points |
| Q2 2026 | 19% | +2.7 points |
| Q1 2026 | 17% | +0.8 points |
| Q4 2025 | 13% | +0.2 points |
| Q3 2025 | 16% | -1.1 points |
| Q2 2025 | 16% | -1.3 points |
| Q1 2025 | 16% | -0.1 points |
| Q4 2024 | 13% | +1.6 points |
CON's operating margin was 19% last quarter, up 2 points from the same quarter a year ago.
CON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $29.4M | -25% |
| Q2 2026 | $119.5M | +89% |
| Q1 2026 | $9.9M | +$14M |
| Q4 2025 | $98.5M | +28% |
| Q3 2025 | $39.4M | -22% |
| Q1 2025 | -$4M | -115% |
| Q4 2024 | $77M | +47% |
| Q3 2024 | $50.8M | +18% |
CON generated $257M in free cash flow over the past year, up 47% from the year before.
CON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -683K shares |
| 1 year | -0.8% | -1.1M shares |
| 3 years | +0.4% | +510K shares |
CON has 127M diluted shares, down 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $34.7M |
| Q2 2026 | $11M |
| Q1 2026 | $15M |
| Q4 2024 | $15.4M |
| Q1 2024 | — |
| Q4 2023 | $5.3M |
| Q3 2023 | — |
| Q2 2023 | — |
CON Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.5x | Elevated |
| Q4 2025 | 3.7x | Elevated |
| Q3 2025 | 4.0x | Elevated |
| Q2 2025 | 4.2x | High |
| Q1 2025 | 4.2x | High |
| Q4 2024 | -0.5x | Net Cash |
CON's net debt is about 3.0 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
CON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 88.2 | Overbought |
| Stochastic | 88.4 | Overbought |
CON's weekly RSI is 88 (overbought) and its Stochastic is 88 (overbought).
CON PE vs Healthcare Sector
| Metric | CON | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 1.6% below |
| PE % | 99 | 54 | 45 pts above |
CON is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
CON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $38.9 | 11% above |
| 20 week MA | $35.7 | 21% above |
| 50 week MA | $28.1 | 53% above |
| 100 week MA | $24.6 | 75% above |
CON is in an uptrend: it's above all four of its weekly moving averages, and 75% above its 100-week average.
CON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $22.9 | $20.4 | -11% |
| 2025 | $20.4 | $20.0 | -1.8% |
| 2026 YTD | $20.0 | $43.0 | +115% |
CON has finished every year since 2024 lower, and it's up 115% so far in 2026.